Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...

Announcing a new article publication for BIO Integration journal.   Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

glucagon-like peptide-1 (GLP-1), and glucagon receptors — experienced the greatest weight loss reductions among the agents studied. Data derived from; Moiz A, et al. Ann Intern Med. 2024 ...

ACCP is a non-profit association providing accredited Continuing Education, publications and career-enhancing opportunities to clinical pharmacology healthcare professionals. We sell different ...

and glucagon receptors with a half-life of 7-8 days in obese/overweight patients with T2D and MASLD. A key differentiator for DD01 lies in its dual pathway mechanism of action. Unlike single and ...

A New Tool for Researchers Developing Dual- and Triple-Agonist Therapies for Obesity, Diabetes, and Other Metabolic Disorders STATE COLLEGE, PA, UNITED STATES, January 28, 2025 /EINPresswire ...